Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

March 2, 2018: By Joan McKenna

Valeant reported Feb. 28 that its 2017 revenues totaled $8.72 billion, a 10 percent decrease from 2016 revenues of $9.67 billion.

The company said its Bausch + Lomb/International segment accounted for 56 percent of total revenues in 2017.

Valeant said its revenue decline was partially offset by higher volumes in the Bausch + Lomb/International segment, primarily the US Consumer Products business, and increased international pricing in the segment.

Bausch + Lomb posted 2017 revenues of $4.87 billion, a drop of 1 percent from 2016 revenues of $4.93 billion.

Bausch + Lomb’s Q4-2017 revenues were $1.23 billion, a decline of 3 percent from Q4-2016 revenues of $1.26 billion.

Valeant said it reduced its debt by more than $4.4 billion in 2017. It also reduced debt repayment requirements through 2020 by more than $10.8 billion since Dec. 31, 2016, and eliminated all long-term debt maturities until 2020 and all mandatory amortization requirements.

CEO Joseph C. Papa called 2017 “a year of strong progress for Valeant.”

The company provided guidance for 2018 of $8.10 billion to $8.30 billion in revenues.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023